

**Sepsis: Recognition, diagnosis and early management guideline (update)  
committee 2 meeting minutes**

**Sepsis: recognition, diagnosis and early management – Committee Meeting 2**

**Date:** 13/09/2022

**Location:** Virtual

**Minutes:** Final

<b>Committee members present:</b>		
Ann Hoskins (Chair, AH)		Present for notes 1 – 6
Samina Begum		Present for notes 1 – 6
Tumena Corrah		Present for notes 1 – 6
Savio Fernandes		Present for notes 1 – 6
Peter Gosling		Present for notes 1 – 6
Alasdair Gray		Present for notes 1 – 6
Jeremy Henning		Present for notes 1 – 6
Erum Khan		Present for notes 1 – 6
Marlies Ostermann		Present for notes 1 – 4
Giovanni Satta		Present for notes 1 – 6
Sally Wood		Present for notes 1 – 6
Tessa Lewis		Present for notes 1 – 6

<b>In attendance:</b>		
Astrid Aregui (AA)	Medical Editor	Present for notes 1 – 6
Victoria Axe	Guideline Commissioning Manager	Present for notes 1 – 6
Cheryl Hookway	Health Technology Adoption Manager	Present for notes 1 – 6
Kirsty Hounsell (KH)	Technical Analyst, Health Economics	Present for notes 1 – 6
Jackie Durkin	Administrator	Present for note 1
Caroline Mulvihill (CM)	Technical Adviser	Present for notes 1 – 6
Jon Littler (JL)	Project Manager	Present for notes 1 – 6
Lindsay Claxton (LC)	Technical Adviser, Health Economics	Present for notes 1 – 6
Teuta Gjuladin-Hellon (TGH)	Technical Analyst	Present for notes 1 – 6
<b>Apologies:</b>		
Louise Bradbury	Committee Member	
Barry Murphy-Jones	Committee Member	
Daniel Tuvey	Information Specialist	

**1. Welcome and objectives for the meeting**

## **Sepsis: Recognition, diagnosis and early management guideline (update) committee 2 meeting minutes**

The Chair (AH) welcomed the committee members and NICE attendees to the first sepsis guideline committee meeting.

AH then informed the committee that apologies had been received which are noted above.

AH then outlined the objectives of the meeting before asking all committee members to verbally declare any interests that have arisen since the last meeting. The committee had no further interests to share other than those already on the existing register and senior members of the Development team noted that the interests already declared did not prevent the attendees from fully participating in the meeting.

Finally, AH introduced Chery Hookway, who gave a brief introduction to her work with NICE's implementation team and how they would be working alongside the development team throughout this update and after publication.

### **2. Clinical evidence presentation and discussion – Evidence review for antibiotic treatment in people with suspected sepsis**

AH introduced Teuta Gjuladin-Hellon (TGH) who began presenting the clinical evidence for the second evidence review – antibiotic treatment in people with suspected sepsis.

After presenting her findings, TGH took questions and comments from the committee before AH thanked the committee for their input, closed this section of the meeting, and moved to item 3.

### **3. Health economic overview**

AH introduced Kirsty Hounsell (KH) who guided the committee through the cost-effectiveness review for this guideline, looking at the various timing of antibiotic administration, summarising the costs and economic considerations of the options.

KH then fielded comments and questions from the committee before AH thanked KH and the committee for their contributions and moved to the next item on the agenda.

### **4. Drafting recommendations – Evidence review for antibiotic treatment in people with suspected sepsis**

AH introduced Caroline Mulvihill (CM) who led the committee on a discussion to draft recommendations based on the evidence they had been shown earlier that day.

### **5. Revisiting recommendations – Evidence review for stratifying risk of severe illness or death from sepsis**

CM returned to take the committee back through the recommendations they had drafted at the first committee meeting, reminding them of their suggestions and checking they had been properly captured.

AH thanks CM for her presentation, and the work of team in incorporating the committee's suggestions and moved on to the final item of the day.

### **6. AOB, Summary and next steps**

JL advised the committee of the next steps and key dates in development leading up to the consultation on this guideline, including that they would be sent redrafts of the recommendations and evidence review, with changes based on their comments and feedback at the meeting.

AH thanked everyone for their attendance and contributions and closed the meeting.

**Sepsis: Recognition, diagnosis and early management guideline (update)  
committee 2 meeting minutes**

**Date of next meeting:** 11/10/2022

**Location of next meeting:** Virtual